Aerosolized clenbuterol (NAB 365) and salbutamol in exercise-induced asthma.
The effect of clenbuterol (NAB 365) in inhibiting exercise-induced asthma was compared with that of salbutamol in a single-blind, placebo-controlled, crossover study. Single doses of 20 microgram clenbuterol and 200 microgram salbutamol were given by inhalation 180 minutes before exercise to 9 patients. The exercise used was treadmill running. Clenbuterol offered complete protection to 7 patients, partial protection to 1 and no protection to 1 patient. Salbutamol offered complete protection to 5 patients, partial protection to 1 and no protection to 3 patients. One patient was not protected by any treatment. The protective effects of the two beta-adrenergic bronchodilator drugs were similar (p = 0.42 for FEV1 and p = 0.10 for FEF25-75%). Placebo failed to prevent exercised-induced asthma in any patient. No adverse reactions were manifested or reported by the patients.
D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000420:Albuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D002648:Child; D002976:Clenbuterol / Q000008:administration & dosage / Q000627:therapeutic use*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male; D005082:Physical Exertion; D012129:Respiratory Function Tests; D013997:Time Factors
D000336:Aerosols; D004983:Ethanolamines; D000420:Albuterol; D002976:Clenbuterol